ArticleBritish journal of cancer2001
Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 119 citations in OpenAlex.
- Article
- Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.Cancer reports (Hoboken, N.J.) · 2020Article
- The prognostic significance of co-existence ductal carcinomaAnnals of translational medicine · 2019Article
- Role of Plasma D-Dimer Levels in Breast Cancer Patients and Its Correlation with Clinical and Histopathological Stage.Indian journal of surgical oncology · 2018Article
- Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.Cancer management and research · 2018Article
- The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.BMC cancer · 2015Article
- Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.Bioscience reports · 2014Review
- Review
- Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations.Cell cycle (Georgetown, Tex.) · 2014Article
- Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.International journal of breast cancer · 2014Article
- Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.BMC cancer · 2013Article
- Ductal carcinoma in situ: a rose by any other name.Journal of the National Cancer Institute · 2013Article
- Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.Medical oncology (Northwood, London, England) · 2012Article
- Angiogenesis in the progression of breast ductal proliferations.International journal of surgical pathology · 2011Article
- Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.Journal of Cancer · 2011Article
- A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy.International journal of breast cancer · 2011Article
- Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.Cancer research · 2010Article
- Mutations in p53, p53 protein overexpression and breast cancer survival.Journal of cellular and molecular medicine · 2009Article
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Experimental and molecular pathology · 2009Review
- Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line.BMC medical genomics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ductal breast carcinoma in situ (DCIS) is regarded as a precursor to invasive breast cancer. The progression from in situ to invasive cancer is however little understood. We compared some tumour markers in invasive and in situ breast carcinomas trying to find steps in this progression. We designed a semi-experimental setting and compared histopathological grading and tumour marker expression in pure DCIS (n = 194), small invasive lesions (n = 127) and lesions with both an invasive and in situ component (n = 305). Grading was done according to the Elston-Ellis and EORTC classification systems, respectively. Immunohistochemical staining was conducted for p53, c-erbB-2, Ki-67, ER, PR, bcl-2 and angiogenesis. All markers correlated with grade rather than with invasiveness. No marker was clearly associated with the progression from in situ to invasiveness. The expression of tumour markers was almost identical in the 2 components of mixed lesions. DCIS as a group showed a more 'malignant picture' than invasive cancer according to the markers, probably, due to a higher proportion of poorly differentiated lesions. The step between in situ and invasive cancer seems to occur independently of tumour grade. The results suggest that well-differentiated DCIS progress to well-differentiated invasive cancer and poorly differentiated DCIS progress to poorly differentiated invasive cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.